Last reviewed · How we verify
STP206
At a glance
| Generic name | STP206 |
|---|---|
| Sponsor | Leadiant Biosciences, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- STP206 for the Prevention of Necrotizing Enterocolitis (NEC) (PHASE1)
- Safety and Tolerability of STP206 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STP206 CI brief — competitive landscape report
- STP206 updates RSS · CI watch RSS
- Leadiant Biosciences, Inc. portfolio CI